- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 478
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Duchenne Muscular Dystrophy, Cardiomyopathy
- Interventions
- Allogeneic Cardiosphere-Derived Cells (CAP-1002)
- Drug
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- onasemnogene abeparvovec
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SRP-4045, SRP-4053, Placebo
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 13 Years · Male only
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Healthy Volunteer, Becker Muscular Dystrophy
- Interventions
- EDG-5506, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Congenital Myotonic Dystrophy
- Interventions
- Tideglusib, Placebo
- Drug
- Lead sponsor
- AMO Pharma Limited
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 6 more
- Conditions
- PolG, Primary Mitochondrial Myopathy
- Interventions
- Not listed
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Kingston, Massachusetts
- Conditions
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
- Interventions
- Ataluren, Chronic Corticosteroid Therapy
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 5
- States / cities
- Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
- Conditions
- Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis
- Interventions
- Dichlorphenamide (double-blind), Placebo (double-blind), Dichlorphenamide (open-label)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Kansas City, Kansas + 7 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 13 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Prednisone
- Drug
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 4 Years to 10 Years · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 100 Years
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2099
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 2 Years to 7 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more
- Conditions
- Mitochondrial Diseases
- Interventions
- EPI-743
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 1 Year and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 12 more
- Conditions
- X-linked Myotubular Myopathy
- Interventions
- Not listed
- Lead sponsor
- Cure CMD
- Other
- Eligibility
- Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Muscular Dystrophy, Muscular Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 5 Years to 17 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Testing with EIM
- Other
- Lead sponsor
- Dart Therapeutics. LLC
- Other
- Eligibility
- 3 Years to 12 Years · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 2 Years to 30 Years · Male only
- Enrollment
- 551 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2019
- U.S. locations
- 11
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
- Conditions
- Muscular Dystrophy, Facioscapulohumeral
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Iowa City, Iowa • Kansas City, Kansas + 3 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years to 21 Years · Male only
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Orange, California • Stanford, California
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Prednisone, Coenzyme Q10
- Drug · Dietary Supplement
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 10 Years to 18 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- VX-670
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Winston-Salem, North Carolina • Richmond, Virginia